JillPSmithMD

Gastroenterology • Washington, DC

Hepatology & Liver Transplantation, Pancreas Disease

Professor, Medicine, Georgetown University College of Medicine

Join to view full profile

Dr. Smith is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Smith's full profile

Already have an account?

Office
3800 Reservoir Rd NW
Pasquerilla Healthcare Center, 6th Floor
Washington, DC 20007
Phone+1 202-444-8168

Fax+1 877-303-1460

Summary

Dr. Jill Smith is a Clinician Scientist that is involved in treating patients, carrying out translational research lab, and she teaches and mentors graduate, medical students, residents and fellows. She is a board certified internist /gastroenterologist in Washington, DC and Full Professor at Georgetown University. She also sees veterans at the Washington DC Veterans Affairs Medical Center in the Hepatology clinics. She received her medical degree from University of Florida College of Medicine and did her residency / fellowship at University of Missouri. She specializes in hepatology & liver transplantation and pancreas diseases. She has more than 100 publications and over 500 citings.

Education & Training

University of Missouri-ColumbiaFellowship, Gastroenterology, 1985 - 1987
University of Missouri-ColumbiaResidency, Internal Medicine, 1981 - 1983
University of Florida College of MedicineClass of 1980

Certifications & Licensure

DC State Medical License 2014 - 2024
PA State Medical License 1987 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

Innovator of the Year award Georgetown University, 2024
Harrington Discovery Scholar Innovator Award Cleveland Clinics- Harrington, 2021
Biochemistry Graduate School Mentoring Award Georgetown University, 2019
Physician of the Year HealthCare Heros- Commonwealth of Pennsylvania, 2013
Department of Medicine Mentoring & Educator Award Penn State Hershey Medical Center, 2012
AOA Penn State University, 1997
Join now to see all

Clinical Trials

Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery Start of enrollment: 2003 Oct 01
Completed
Phase 2
The Effects of Naltrexone on Active Crohn's Disease Start of enrollment: 2006 Sep 01
Completed
Phase 2
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor Start of enrollment: 2008 Jun 01
Completed
Phase 1
The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease Start of enrollment: 2008 Jul 01
Completed
Phase 2
Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer Start of enrollment: 2009 Jan 01
Terminated
Phase 1
Safety and Tolerability of Oral Proglumide for NASH Start of enrollment: 2019 Dec 13
Completed
Phase 1
Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment Start of enrollment: 2021 Mar 30
Completed
Early Phase 1
Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis Start of enrollment: 2022 Nov 17
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

5 citations
Functional characterization of a chr13q22.1 pancreatic cancer risk locus reveals long-range interaction and allele-specific effects on DIS3 expression.
Jason W Hoskins, Abdisamad Ibrahim, Mickey A Emmanuel, Sarah M Manmiller, Yinglun Wu
Human Molecular Genetics. 2016-11-01
28 citations
Characterization of CCK-B/gastrin-like receptors in human gastric carcinoma.
Jill P. Smith, Alan H. Shih, Michael G. Wotring, Patricia J. McLaughlin, Ian S. Zagon
International Journal of Oncology. 1998-02-01
30 citations
Characterization of the CCK-B/gastrin-like receptor in human colon cancer
Jill P. Smith, Elizabeth Stock, Michael G. Wotring, Patricia J. McLaughlin, Ian S. Zagon
The American Journal of Physiology. 1996-09-01

Journal Articles

Cholecystokinin and pancreatic cancer: the chicken or the egg?
Smith JP, Solomon TE, Gastrointest Liver Physiol 2014;306:G91-G101
Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice
Smith JP, Cooper TK, McGovern CO, et al, Pancreas 2014;43:1050-9

Press Mentions

Cancer Advances, Inc. Announces Publication, "Gastrin Vaccine Alone and in Combination with an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer" in Frontiers in OncologyDecember 6th, 2021
Cancer Advances, Inc. Announces Publication, “Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model" in Cancer Prevention ResearchAugust 24th, 2021
Naltrexone at Low Doses Upregulates a Unique Gene Expression Not Seen with Normal Doses: Implications for Its Use in Cancer TherapySeptember 27th, 2016

Grant Support

The CCK-B receptor signaling pathway as a driver of pancreatic cellular plasticity and carcinogenesisNIH /NCI2023–2028
Activation of Cholecystokinin-B Receptor-Positive Stem Cells Induces Hepatic CarcinogenesisDOD2021–2024
Targeted nanoparticle for early diagnosis & treatment of pancreatic cancerAACR2021–2023
Proglumide and the Pancreatic Tumor MicroenvironmentPancreatic Action Network2020–2023
Phase 1 study to test safety and dose of proglumide as an anti-fibrotic agentNCI2019–2021
High fat diet stimulates pancreatic cancer through the actions of CholecystokininNCI2015–2018
The Cholecystokinin-C (Cck-C) Receptor For Early Detection Of Pancreatic CancerNational Cancer Institute2007–2010
The Efficacy Of Low Dose Naltrexone Therapy In Children With Crohn'SNational Center For Research Resources2009
Clinical Trial: OGF &Gemcitabine: Novel Treatment For Pancreatic CancerNational Center For Research Resources2009
OGF &Gemcitabine: A Novel Treatment For Pancreatic Cancer: Phase I StudyNational Cancer Institute2008–2009
The Effects Of Naltrexone On Active Crohn'S DiseaseNational Center For Research Resources2007–2009
Effects Of Silencing RNAS For Gastrin And CCK On Human Pancreatic CancerNational Cancer Institute2007–2008
Treatment Of Advanced Pancreatic Cancer With Opioid Growth Factor Phase IINational Center For Research Resources2005–2008
Effects Of Naltrexone On Active Crohn'S DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2006–2007
Efficacy Of Low Dose Naltrexone Therapy In Crohn'S DiseaseNational Center For Research Resources2005–2006
Treatment Of Advanced Pancreatic Cancer With Growth Fac*Food And Drug Administration2005
Low Dose Naltrexone Therapy In Crohn'S DiseaseNational Center For Research Resources2004
Gastrointestinal Peptides And Pancreatic CancerNational Cancer Institute2001–2004
Peptides And Pancreatic CancerNational Cancer Institute2002–2003
Treatment Of Hepatitis C With Amantadine: Dose Escalation StudyNational Center For Research Resources2000–2002
Treating Advanced Pancreatic Cancer With Opioid Growth Factor, Phase INational Center For Research Resources2000–2002
Treatment Of Chronic Hepatitis C With Amantadine HydrochlorideNational Center For Research Resources1997–2002
Peptides And Pancreatic CanerNational Cancer Institute1999–2001
Opioid Growth Factor And Pancreatic Cancer--Phase 1National Cancer Institute1999–2000
Treatment Of Chronic Hepatitis C With Amantadine Hc1National Institute Of Allergy And Infectious Diseases1998–1999
Cholecystokinin Of Pancreatic CancerNational Cancer Institute1995–1997
Effects Of Cholecystokinin On Human Pancreatic CancerNational Cancer Institute1989–1993